Real-World Asthma Control
Asthma-related outcomes in 1569 patients starting therapy with QVAR® were evaluated in a 1-year, observational, retrospective, matched-cohort analysis of patients 5-60 years of age in the UK's General Practice Research Database (GPRD).1 86% of patients initiated on QVAR® achieved asthma control at a low* mean dose of 198 µg/day. 82% of patients stepped up on QVAR® achieved asthma control at a medium* mean dose of 339 µg/day. Asthma control was defined as no recorded hospital attendance for asthma, no prescription for oral corticosteroid, and no consultation, hospital admission, or emergency department attendance for lower respiratory tract infection requiring antibiotics.1
*Based on the NIH Estimated QVAR® Daily Dosage Ranges for Youths ≤ 12 Years of Age and Adults.2
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm.
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment
Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9% respectively) and pharyngitis (8% and 4% respectively).